Increased atherosclerotic lesion area in apoE deficient mice overexpressing bovine growth hormone

Atherosclerosis

Volumn 188, Issue 2, 2006, Pages 331-340

  Andersson, Irene J ^a   Ljungberg, Anna ^a,b   Svensson, Lennart ^c   Gan, Li Ming ^a,c,d   Oscarsson, Jan ^a,b,c   Bergström, Göran ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Apolipoprotein E; Atherogenic; Atherosclerosis; Diet; Growth hormone

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; GROWTH HORMONE; LIVER PROTEIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; DISEASE SEVERITY; EXPERIMENTAL MODEL; GROWTH HORMONE RELEASE; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTENSION; HYPOTHESIS; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STANDARD; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; TRANSGENIC MOUSE;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CROSSES, GENETIC; DIET; DISEASE MODELS, ANIMAL; DNA PRIMERS; GROWTH HORMONE; MICE; MICE, KNOCKOUT; SERUM AMYLOID A PROTEIN;

EID: 33748053656     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.11.020     Document Type: Article

References (38)

1. Sowers J.R. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 29 3 (1997) 691-699
2. Bengtsson B.A., et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223 4 (1988) 327-335
3. Colao A., et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25 1 (2004) 102-152
4. Poulter N. Global risk of cardiovascular disease. Heart 89 90002 (2003) 2-5
5. Otsuki M., et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 54 6 (2001) 791-796
6. Frick F., et al. Long-term growth hormone excess induces marked alterations in lipoprotein metabolism in mice. Am J Physiol Endocrinol Metabol 281 6 (2001) E1230-E1239
7. Bohlooly Y.M., et al. Vascular function and blood pressure in GH transgenic mice. Endocrinology 142 8 (2001) 3317-3323
8. Olsson B., et al. Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology 146 2 (2005) 920-930
9. Andersson IJ, et al. Endothelial dysfunction in growth hormone transgenic mice. Clin Sci (Lond), in press (Epub ahead of print).
10. Nakashima Y., et al. apoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14 1 (1994) 133-140
11. Sandstedt J., et al. Disproportional bone growth and reduced weight gain in gonadectomized male bovine growth hormone transgenic and normal mice. Endocrinology 135 6 (1994) 2574-2580
12. Andersson I.J., et al. Reduced sympathetic responsiveness as well as plasma and tissue noradrenaline concentration in growth hormone transgenic mice. Acta Physiol Scand 182 4 (2004) 369-378
13. Paigen B., et al. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68 3 (1987) 231-240
14. Russell Jr. H.K. A modification of Movat's pentachrome stain. Arch Pathol 94 2 (1972) 187-191
15. van Vlijmen B.J., et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93 4 (1994) 1403-1410
16. Linden D., et al. PPARalpha deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins. J Lipid Res 42 11 (2001) 1831-1840
17. Oscarsson J., et al. Differential effects of continuous versus intermittent administration of growth hormone to hypophysectomized female rats on serum lipoproteins and their apoproteins. Endocrinology 125 3 (1989) 1638-1649
18. Bohlooly Y.M., et al. Enhanced spontaneous locomotor activity in bovine GH transgenic mice involves peripheral mechanisms. Endocrinology 142 10 (2001) 4560-4567
19. Daugherty A., Manning M.W., and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105 11 (2000) 1605-1612
20. -/- mice. J Hypertens 23 8 (2005) 1541-1549
21. Caligiuri G., et al. Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis 145 2 (1999) 301-308
22. Reddick R.L., Zhang S.H., and Maeda N. Atherosclerosis in mice lacking apoE. Evaluation of lesional development and progression. Arterioscler Thromb 14 1 (1994) 141-147
23. Tulenko T.N., and Sumner A.E. The physiology of lipoproteins. J Nucl Cardiol 9 6 (2002) 638-649
24. Austin M.A. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 83 9B (1999) 13F-16F
25. Sniderman A.D., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 9359 (2003) 777-780
26. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 2 (1999) 115-126
27. Johnson B.D., et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation (WISE). Circulation 109 6 (2004) 726-732
28. Olsson B., et al. Bovine growth hormone-transgenic mice have major alterations in hepatic expression of metabolic genes. Am J Physiol Endocrinol Metabol 285 3 (2003) E504-E511
29. Lewis K.E., et al. Increase in serum amyloid A evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 110 5 (2004) 540-545
30. Torzewski M., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20 9 (2000) 2094-2099
31. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 9 (2001) 1194-1197
32. Paul A., et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109 5 (2004) 647-655
33. Sesmilo G., et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metabol 87 4 (2002) 1692-1699
34. Ku N.O., and Mortensen R.F. The mouse C-reactive protein (CRP) gene is expressed in response to IL-1 but not IL-6. Cytokine 5 4 (1993) 319-326
35. Bengtsson B.A., Brummer R.J., and Bosaeus I. Growth hormone and body composition. Horm Res 33 Suppl. 4 (1990) 19-24
36. Delafontaine P., Song Y.-H., and Li Y. Expression regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24 3 (2004) 435-444
37. Ledet T. Growth hormone stimulating the growth of arterial medial cells in vitro. Absence of effect of insulin. Diabetes 25 11 (1976) 1011-1017
38. Hochberg Z., et al. Growth hormone and insulin-like growth factor-I increase macrophage uptake and degradation of low density lipoprotein. Endocrinology 131 1 (1992) 430-435